核酸检测反应性献血者归队方法学及可行性的初步研究

发布时间：2018-05-13 18:35

  本文选题：NAT反应性 + 献血者归队　； 参考：《中国输血杂志》2017年07期

【摘要】：目的实验探讨NAT反应性献血者归队的方法和可行性。方法挑选2012年-2014年ELISA无反应性NAT反应性献血者,获其知情同意后召回收集血样。先进行常规ELISA(HBs Ag、抗-HCV、抗-HIV和抗-TP)和NAT(HBV-DNA、HCV-RNA和HIV-RNA)检测。若均为无反应性的,再继续进行高灵敏度的化学发光法补充试验(HBs Ag、HBe Ag、抗-HBs、抗-HBc、抗-HBe、抗-HCV、抗-HIV)。结果召回献血者30人,经检测仍为ELISA无反应性NAT反应性的11例,拟建议永久屏蔽;ELISA、NAT均为无反应性的19例,化学发光法检测89.5%为抗-HBc和/或抗-HBe反应性(12例抗-HBc、抗-HBe均反应性,5例抗-HBe反应性)。抗-HBc或抗-HBe反应性存在感染风险,拟建议永久屏蔽。2例所有项目均无反应性,拟建议可以考虑归队。结论 NAT反应性献血者归队有其必要性和现实意义,但为血液安全考虑,应建立1个谨慎的适合中国人群的NAT反应性献血者归队方案。
[Abstract]:Objective to explore the method and feasibility of NAT reactive blood donors. Methods ELISA nonreactive NAT donors were selected from 2012 to 2014 and recalled to collect blood samples with their informed consent. Routine ELISA(HBs Ag, anti-HCV, anti-HIV and anti-TP-) and Nat HBV-DNA HCV-RNA and HIV-RNA were first detected. If all of them were nonreactive, the high sensitivity chemiluminescence supplementation test (HBs Ag-HBe, anti-HBs, anti-HBc, anti--HBe, anti-HCV, anti-HIVP) was carried out. Results Thirty blood donors were recalled, 11 of them were still ELISA nonreactive NAT reactivity, 19 of them were suggested to be permanently shielded from EISANAT. By chemiluminescence assay, 12 cases of anti-HBc and / or anti-HBe reactivity were detected by chemiluminescence assay, and 5 cases of anti-HBe reactivity were detected by anti-HBe reactivity. Anti-HBc or anti-HBe reactivity is at risk of infection. It is suggested that all items should be permanently shielded. Conclusion it is necessary and practical for NAT reactive blood donors to return to China, but for the sake of blood safety, it is necessary to establish a prudent scheme for NAT reactive blood donors in China.
【作者单位】： 上海市血液中心;
【分类号】：R446.6
，

本文编号：1884331